1
|
Lobo J, Lopes P, Henrique R, Rodrigues Â. The enigmatic occurrence of Pacinian corpuscles in the prostate gland: Report of a case with pericorpuscular and intracorpuscular growth of prostatic acinar adenocarcinoma. Pathol Int 2024; 74:48-50. [PMID: 38050798 DOI: 10.1111/pin.13392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2023] [Revised: 11/16/2023] [Accepted: 11/17/2023] [Indexed: 12/06/2023]
Affiliation(s)
- João Lobo
- Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Porto, Portugal
- Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Porto, Portugal
- Department of Pathology and Molecular Immunology, ICBAS-School of Medicine and Biomedical Sciences, University of Porto, Porto, Portugal
| | - Paula Lopes
- Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Porto, Portugal
| | - Rui Henrique
- Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Porto, Portugal
- Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Porto, Portugal
- Department of Pathology and Molecular Immunology, ICBAS-School of Medicine and Biomedical Sciences, University of Porto, Porto, Portugal
| | - Ângelo Rodrigues
- Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Porto, Portugal
- Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Porto, Portugal
- Department of Pathology and Molecular Immunology, ICBAS-School of Medicine and Biomedical Sciences, University of Porto, Porto, Portugal
| |
Collapse
|
2
|
Nova-Camacho LM, Acosta AM, Trpkov K, Sangoi AR, Pierre A, Chou A, Yilmaz A, Morini A, Rodrigues Â, Fletcher CDM, Perez-Montiel D, Maclean F, Contreras F, Queipo FJ, Muñiz Unamunzaga G, Mesa H, de Torres I, Ruiz I, Alvarado-Cabrero I, Lobo J, Schwartz L, Cheng L, Akgul M, García-Martos M, Palmer MB, Aron M, Raspollini MR, Manrique Celada M, Hwang M, Idrees MT, Rioux-Leclercq N, Zalles N, Vergara N, Lal P, Wobker S, Kammerer-Jacquet SF, Prendeville S, Tilmant T, Ulbright TM, Verkarre V, Collins K, Williamson SR, Panizo A. Metastatic solid tumors to the testis: a clinicopathologic evaluation of 157 cases from an international collaboration. Hum Pathol 2023; 139:37-46. [PMID: 37331529 DOI: 10.1016/j.humpath.2023.06.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Revised: 05/31/2023] [Accepted: 06/13/2023] [Indexed: 06/20/2023]
Abstract
To elucidate the spectrum of metastatic solid tumors to the testis and their clinicopathologic features. The databases and files of 26 pathology departments from 9 countries on 3 continents were surveyed to identify metastatic solid tumors to the testis and to characterize their clinicopathologic features in detail. We compiled a series of 157 cases of metastatic solid tumors that secondarily involved the testis. The mean patient age at diagnosis was 64 years (range, 12-93 years). Most patients (127/144; 88%) had clinical manifestation of the disease, with testicular mass/nodule (89/127; 70%) being the most common finding. The main mechanism of testicular involvement was metastasis in 154/157 (98%) cases. Bilateral testicular involvement was present in 12/157 (8%) patients. Concurrent or prior extratesticular metastases were present in 78/101 (77%) patients. The diagnosis was made mainly in orchiectomy specimens (150/157; 95%). Different types of carcinomas (138/157; 87%), most commonly adenocarcinoma (72/157; 46%), were the most common malignancies. The most common primary carcinomas included prostatic (51/149; 34%), renal (29/149; 20%), and colorectal (13/149; 9%). Intratubular growth was identified in 13/124 (11%) cases and paratesticular involvement was found in 73/152 (48%) cases. In patients with available follow-up (110/157; 70%), more than half (58/110; 53%) died of disease. In this largest series compiled to date, we found that most secondary tumors of the testis represent metastases from the genitourinary and gastrointestinal tract carcinomas and typically occur in the setting of disseminated disease.
Collapse
Affiliation(s)
- Luiz M Nova-Camacho
- Department of Pathology, Donostia University Hospital, San Sebastian 20014, Spain.
| | - Andres M Acosta
- Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA 02115, USA; Department of Pathology, Faulkner Hospital, Boston, MA 02130, USA
| | - Kiril Trpkov
- Department of Pathology and Laboratory Medicine, University of Calgary, Calgary T2V 1P9, Canada
| | - Ankur R Sangoi
- Department of Pathology, El Camino Hospital, Mountain View, CA 94040, USA
| | - Allaume Pierre
- Department of Pathology, CHU Rennes - Hôpital Pontchaillou, Rennes 35000, France
| | - Angela Chou
- Department of Anatomical Pathology, Royal North Shore Hospital and University of Sydney, Sydney 2065, Australia
| | - Asli Yilmaz
- Department of Pathology and Laboratory Medicine, University of Calgary, Calgary T2V 1P9, Canada
| | - Aurélien Morini
- Department of Pathology, Grand Hôpital de L'Est Francilien, Jossigny, Ile-de-France 77600, France
| | - Ângelo Rodrigues
- Department of Pathology, Portuguese Oncology Institute of Porto, Porto 4200-072, Portugal
| | - Christopher D M Fletcher
- Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA 02115, USA
| | - Delia Perez-Montiel
- Department of Pathology, Instituto Nacional de Cancerología, Mexico City 14080, Mexico
| | - Fiona Maclean
- Department of Pathology and Laboratory Medicine, Douglass Hanly Moir Pathology, Sonic Healthcare, Sydney 2000, Australia
| | - Félix Contreras
- Laboratorio de Patología, Clínica Universitaria Unión Médica, PUCMM, Santiago 51000, Dominican Republic
| | | | | | - Hector Mesa
- Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | - Inés de Torres
- Department of Pathology, Vall D'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona 08035, Spain
| | - Irune Ruiz
- Department of Pathology, Donostia University Hospital, San Sebastian 20014, Spain
| | - Isabel Alvarado-Cabrero
- Department of Pathology Oncology, Star Medica Hospital, Oncology Hospital, IMSS, Mexico City 03810, Mexico
| | - João Lobo
- Department of Pathology, Portuguese Oncology Institute of Porto, Porto 4200-072, Portugal; Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), Porto 4200-072, Portugal; Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Porto 4050-313, Portugal
| | - Lauren Schwartz
- Department of Pathology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Liang Cheng
- Department of Pathology and Laboratory Medicine, Brown University Warren Alpert Medical School, Providence, RI 02903, USA
| | - Mahmut Akgul
- Department of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY 12208, USA
| | - María García-Martos
- Department of Pathology, Gregorio Marañón University Hospital, Madrid 28007, Spain
| | - Matthew B Palmer
- Department of Pathology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Manju Aron
- Department of Pathology and Laboratory Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| | | | | | - Michael Hwang
- Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | - Muhammad T Idrees
- Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | | | - Nicole Zalles
- Department of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, OH 44106, USA
| | - Norge Vergara
- Department of Pathology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Priti Lal
- Department of Pathology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Sara Wobker
- Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| | | | - Susan Prendeville
- Laboratory Medicine and Pathobiology, University of Toronto, Toronto M5S 1A1, Canada
| | - Théau Tilmant
- Department of Pathology, European Georges Pompidou Hospital, Université Paris-Cité, Paris 75015, France
| | - Thomas M Ulbright
- Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | - Virginie Verkarre
- Department of Pathology, European Georges Pompidou Hospital, Université Paris-Cité, Paris 75015, France
| | - Katrina Collins
- Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | - Sean R Williamson
- Department of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, OH 44106, USA
| | - Angel Panizo
- Department of Pathology, University Hospital of Navarra, Pamplona 31008, Spain
| |
Collapse
|
3
|
Lobo J, Tavares NT, Barros-Silva D, Rosinha A, Morais A, Jerónimo C, Rodrigues Â, Henrique R. MiR-371a-3p in cystic trophoblastic tumour of the testis: supporting a maturation phenomenon towards teratoma. Histopathology 2023. [PMID: 37099411 DOI: 10.1111/his.14929] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2023] [Revised: 03/17/2023] [Accepted: 04/09/2023] [Indexed: 04/27/2023]
Affiliation(s)
- João Lobo
- Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), Porto, Portugal
- Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), Porto, Portugal
- Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Porto, Portugal
| | - Nuno Tiago Tavares
- Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), Porto, Portugal
| | - Daniela Barros-Silva
- Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), Porto, Portugal
| | - Alina Rosinha
- Department of Medical Oncology, Portuguese Oncology Institute of Porto (IPOP), Porto, Portugal
| | - António Morais
- Department of Urology, Portuguese Oncology Institute of Porto (IPOP), Porto, Portugal
| | - Carmen Jerónimo
- Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), Porto, Portugal
- Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Porto, Portugal
| | - Ângelo Rodrigues
- Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), Porto, Portugal
- Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), Porto, Portugal
- Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Porto, Portugal
| | - Rui Henrique
- Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), Porto, Portugal
- Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), Porto, Portugal
- Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Porto, Portugal
| |
Collapse
|
4
|
Nova-Camacho LM, Collins K, Trpkov K, Acosta AM, Sangoi AR, Akgul M, Chou A, Polonia A, Rodrigues Â, Yilmaz A, Perez-Montiel D, Maclean F, Queipo Gutiérrez FJ, Contreras F, Wu HH, Alvarado-Cabrero I, de Torres I, Ruiz I, Lobo J, Prendeville S, Manrique Celada M, Cheng L, Galea LA, Hwang M, Aron M, García-Martos M, Zalles N, Raspollini MR, Williamson SR, Ulbright TM, Panizo A. Metastatic solid tumours to the penis: a clinicopathologic evaluation of 109 cases from an international collaboration. Histopathology 2023. [PMID: 37071396 DOI: 10.1111/his.14927] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2023] [Revised: 03/21/2023] [Accepted: 04/01/2023] [Indexed: 04/19/2023]
Abstract
AIMS To elucidate the spectrum of metastatic tumours to the penis and their clinicopathologic features. METHODS The databases and files of 22 pathology departments from eight countries on three continents were queried to identify metastatic solid tumours of the penis and to characterize their clinical and pathologic features. RESULTS We compiled a series of 109 cases of metastatic solid tumours that secondarily involved the penis. The mean patient age at diagnosis was 71 years (range, 7-94 years). Clinical presentation commonly included a penile nodule/mass (48/95; 51%) and localised pain (14/95; 15%). A prior history of malignancy was known in 92/104 (89%) patients. Diagnosis was made mainly on biopsy (82/109; 75%), or penectomy (21/109; 19%) specimens. The most common penile locations were the glans (45/98; 46%) and corpus cavernosum (39/98; 39%). The most frequent histologic type was adenocarcinoma (56%). Most primary carcinomas originated in the genitourinary (76/108; 70%) and gastrointestinal (20/108; 18%) tracts, including prostate (38/108; 35%), urinary bladder (27/108; 25%), and colon/rectum (18/108; 17%). Concurrent or prior extrapenile metastases were identified in 50/78 (64%) patients. Clinical follow-up (mean 22 months, range 0-171 months) was available for 87/109 (80%) patients, of whom 46 (53%) died of disease. CONCLUSION This is the largest study to date of metastatic solid tumours secondarily involving the penis. The most frequent primaries originated from the genitourinary and gastrointestinal tracts. Metastatic penile tumours usually presented with penile nodules/masses and pain, and they often occurred in the setting of advanced metastatic disease, portending poor clinical outcomes.
Collapse
Affiliation(s)
| | - Katrina Collins
- Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Kiril Trpkov
- Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada
| | - Andres M Acosta
- Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA
| | - Ankur R Sangoi
- Department of Pathology, El Camino Hospital, Mountain View, CA, USA
| | - Mahmut Akgul
- Department of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY, USA
| | - Angela Chou
- Department of Anatomical Pathology, Royal North Shore Hospital and University of Sydney, Sydney, NSW, Australia
| | - Antonio Polonia
- Ipatimup-Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal
| | - Ângelo Rodrigues
- Department of Pathology, Portuguese Oncology Institute of Porto, Porto, Portugal
| | - Asli Yilmaz
- Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada
| | - Delia Perez-Montiel
- Department of Pathology, Instituto Nacional de Cancerología, Mexico City, Mexico
| | - Fiona Maclean
- Department of Pathology and Laboratory Medicine, Douglass Hanly Moir Pathology, Sonic Healthcare, Sydney, NSW, Australia
| | | | - Félix Contreras
- Laboratorio de Patología, Clínica Universitaria Unión Médica, PUCMM, Santiago, Dominican Republic
| | - Howard H Wu
- Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Isabel Alvarado-Cabrero
- Department of Pathology Oncology, Star Medica Hospital, Oncology Hospital, IMSS, Mexico City, Mexico
| | - Inés de Torres
- Department of Pathology, Vall d'Hebron Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Irune Ruiz
- Department of Pathology, Donostia University Hospital, San Sebastian, Spain
| | - João Lobo
- Department of Pathology, Portuguese Oncology Institute of Porto, Porto, Portugal
- Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), Porto, Portugal
- Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Porto, Portugal
| | - Susan Prendeville
- Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
| | | | - Liang Cheng
- Department of Pathology and Laboratory Medicine, Brown University Warren Alpert Medical School, Lifespan Academic Medical Center, and the Legorreta Cancer Center at Brown University, Providence, RI, USA
| | - Laurence A Galea
- Department of Anatomical Pathology, Melbourne Pathology, Sonic Healthcare, Dandenong, Vic., Australia
| | - Michael Hwang
- Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Manju Aron
- Department of Pathology and Laboratory Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - María García-Martos
- Department of Pathology, Gregorio Marañon University Hospital, Madrid, Spain
| | - Nicole Zalles
- Department of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA
| | | | - Sean R Williamson
- Department of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA
| | - Thomas M Ulbright
- Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Angel Panizo
- Department of Pathology, University Hospital of Navarra, Pamplona, Spain
| |
Collapse
|
5
|
Lobo J, Lobo C, Leça L, Rodrigues Â, Henrique R, Monteiro P. Evaluation of the Implementation and Diagnostic Accuracy of the Paris Classification for Reporting Urinary Cytology in Voided Urine Specimens: A Cyto-Histological Correlation Study in a Cancer Center. Pathobiology 2022; 90:233-240. [PMID: 36574757 DOI: 10.1159/000527980] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2022] [Accepted: 11/03/2022] [Indexed: 12/28/2022] Open
Abstract
INTRODUCTION The Paris classification highlights the need to focus on accurately identifying high-grade urothelial carcinoma (HGUC). Herein, we aimed to assess the overall implementation and diagnostic performance of the Paris classification for reporting urinary cytology in a cancer center. METHODS All urinary cytology reports from July 2018 to December 2019 were collected (n = 1,240). Only voided urine samples were included (n = 1,180). Risk of high-grade malignancy (ROHM) was calculated for each Paris category. The diagnostic performance of urinary cytology was assessed, including sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy. RESULTS The distribution of categories was: 0.3% unsatisfactory, 90.5% negative for HGUC, 5.6% atypical urothelial cells (AUC), 1.6% suspicious for HGUC, 1.9% HGUC, and 0.1% other malignancies. No diagnosis of low-grade urothelial neoplasia was given. The ROHM was 21.4% for negative for HGUC, 66.7% for AUC, 91.7% for suspicious for HGUC, and 100% for HGUC. When using suspicious for HGUC as a cutoff, the diagnostic performance of urinary cytology in identifying HGUC histology was 46% sensitivity, 98% specificity, 96% PPV, 68% NPV, and 74% accuracy. CONCLUSION Specificity of urinary cytology was very high (with only 1 false-positive result), which is important since this will trigger a clinical intervention. The ROHM for each category was in accordance with literature, except for AUC where ROHM was slightly higher (66.7%). This may be explained by the study population characteristics (cancer center; many patients treated with intravesical therapies; lack of clinical annotation for patients referred from outside institutions).
Collapse
Affiliation(s)
- João Lobo
- Department of Pathology, Portuguese Oncology Institute of Porto/Porto Comprehensive Cancer Centre (Porto.CCC), Porto, Portugal
- Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Centre (Porto.CCC), Porto, Portugal
- Department of Pathology and Molecular Immunology, School of Medicine & Biomedical Sciences, University of Porto (ICBAS-UP), Porto, Portugal
| | - Cláudia Lobo
- Department of Pathology, Portuguese Oncology Institute of Porto/Porto Comprehensive Cancer Centre (Porto.CCC), Porto, Portugal
| | - Luís Leça
- Department of Pathology, Portuguese Oncology Institute of Porto/Porto Comprehensive Cancer Centre (Porto.CCC), Porto, Portugal
| | - Ângelo Rodrigues
- Department of Pathology, Portuguese Oncology Institute of Porto/Porto Comprehensive Cancer Centre (Porto.CCC), Porto, Portugal
- Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Centre (Porto.CCC), Porto, Portugal
- Department of Pathology and Molecular Immunology, School of Medicine & Biomedical Sciences, University of Porto (ICBAS-UP), Porto, Portugal
| | - Rui Henrique
- Department of Pathology, Portuguese Oncology Institute of Porto/Porto Comprehensive Cancer Centre (Porto.CCC), Porto, Portugal
- Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Centre (Porto.CCC), Porto, Portugal
- Department of Pathology and Molecular Immunology, School of Medicine & Biomedical Sciences, University of Porto (ICBAS-UP), Porto, Portugal
| | - Paula Monteiro
- Department of Pathology, Portuguese Oncology Institute of Porto/Porto Comprehensive Cancer Centre (Porto.CCC), Porto, Portugal
- Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Centre (Porto.CCC), Porto, Portugal
- Department of Pathology and Molecular Immunology, School of Medicine & Biomedical Sciences, University of Porto (ICBAS-UP), Porto, Portugal
| |
Collapse
|
6
|
Lobo J, Rodrigues Â, Henrique R, Christiansen A, Beyer J, Moch H, Bode PK. Morphological spectrum and molecular features of somatic malignant transformation in germ cell tumours. Histopathology 2022; 81:84-98. [PMID: 35438203 DOI: 10.1111/his.14667] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 03/20/2022] [Accepted: 04/16/2022] [Indexed: 11/28/2022]
Abstract
AIMS Somatic malignant transformation (SMT) arising in germ cell tumours (GCTs) is an infrequent, but clinically relevant event. There is only limited knowledge on the morphological spectrum of SMT, and therapeutic management of these patients is poorly defined. In this work we revisit two consecutive case series (n=756) of GCTs. Clinicopathological data of SMT arising in GCT were determined, with focus on the histopathological spectrum, and molecular aspects were obtained by Fluorescence in situ Hybridization (FISH) and Next Generation Sequencing (NGS). METHODS AND RESULTS 30 male patients (28 primary testicular, 2 primary extragonadal) were included. These patients represent 4% of GCT patients diagnosed in two institutes (University Hospital Zurich and IPO Porto). The most common SMT were adenocarcinoma (n=8), embryonic-type neuroectodermal tumours (ENETs, n=8) and rhabdomyosarcoma (n=6), but a wide range of challenging morphologies were depicted, including low-grade neuroglial tumour, adenosquamous carcinoma, neuroblastoma and neuroendocrine carcinoma. SMT was found in 15 primary tumour samples and in 27 metastatic samples of these 30 patients, the latter showing poorer overall-survival. Adenocarcinoma occurred only in metastasis post-chemotherapy and in one primary retroperitoneal GCT with SMT, but not in GCT of the testis. 12p gains were identified by FISH in all cases. NGS results were available in 6 patients. Clinical trials and/or targeted treatments based on the molecular profile of SMT were recommended in 4 patients. CONCLUSIONS SMT arising in GCTs represents a diagnostic challenge and should be confirmed by a specialized uropathologist. NGS based treatment recommendations may improve outcome of these patients.
Collapse
Affiliation(s)
- João Lobo
- Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal.,Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), R. Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal.,Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-, UP, ), Rua Jorge Viterbo Ferreira 228, 4050-513, Porto, Portugal
| | - Ângelo Rodrigues
- Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal.,Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), R. Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal.,Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-, UP, ), Rua Jorge Viterbo Ferreira 228, 4050-513, Porto, Portugal
| | - Rui Henrique
- Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal.,Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), R. Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal.,Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-, UP, ), Rua Jorge Viterbo Ferreira 228, 4050-513, Porto, Portugal
| | - Ailsa Christiansen
- Department of Pathology and Molecular Pathology, University Hospital Zurich, Schmelzbergstrasse 12, CH, 8091, Zurich, Switzerland
| | - Jörg Beyer
- Universitätsklinik für Medizinische Onkologie, Inselspital, Universitätsklinik der Universität Bern, Bern University, Switzerland
| | - Holger Moch
- Department of Pathology and Molecular Pathology, University Hospital Zurich, Schmelzbergstrasse 12, CH, 8091, Zurich, Switzerland.,Faculty of Medicine, University of Zurich, Rämistrasse 71, 8006, Zurich, Switzerland
| | - Peter Karl Bode
- Department of Pathology and Molecular Pathology, University Hospital Zurich, Schmelzbergstrasse 12, CH, 8091, Zurich, Switzerland
| |
Collapse
|
7
|
Almeida R, Abrantes C, Gigliano D, Oliveira RC, Teixeira P, Viegas M, Rodrigues Â, Julião MJ. Clinical and Pathological Features of Double-Hit and Triple-Hit High-Grade B-Cell Lymphomas: A Retrospective Study from Three Portuguese Tertiary Centers. Int J Hematol Oncol Stem Cell Res 2022; 16:94-102. [PMID: 36304730 PMCID: PMC9547779 DOI: 10.18502/ijhoscr.v16i2.9202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2020] [Accepted: 01/03/2022] [Indexed: 11/24/2022] Open
Abstract
Background: High-grade B-cell lymphoma (HGBL) with rearrangements of MYC and BCL2 and/or BCL6, called double and triple-hit lymphomas (DTH-HGBL), are lymphoid malignancies with inferior outcomes when treated with standard chemotherapy. The identification of DTH-HGBL cases is challenging, considering their variable clinical, morphologic, and immunohistochemical features. Materials and Methods: Retrospective revision of medical data of patients diagnosed with DTH-HGBL confirmed by FISH, between January 2010 and January 2020, in three Tertiary Portuguese Hospitals (Coimbra Hospital and University Center, Portuguese Oncology Institute – Coimbra and Portuguese Oncology Institute – Porto). Pathological features, morphology, and immunohistochemical profile were evaluated by at least two experienced pathologists in hematopoietic and lymphoid neoplasms. Results: The cohort included 24 patients: 33.3% triple-hit, 58.3%, MYC/BCL2 double-hit and 8.3% MYC/BCL6 double-hit. There was no gender predominance, with a median age of 62.5±14.3y, 33.3% were diagnosed as nodal disease, and 66.7% as extranodal. Morphologic features of DLBCL were present in 50% of cases, morphological features of both DLBCL and Burkitt lymphoma (DLBCL/BL) in 45.8% and 4.2% of blastoid morphology. Immunohistochemical evaluation, regarding the Hans algorithm, revealed a Germinal center (GC)/GC-like subtype in 83.3% of cases and a non-GC/non-GC-like subtype in 16.7%. MYC was positive in 42.9% and the median proliferative index was 80±12.4%. Conclusion: DTH-HGBL has a very broad range of features. We consider that a cost-effective approach would be to perform cytogenetic analysis in DLBCL and DLBCL/BL cases with GC/GC-like subtype. MYC and BCL2 immunohistochemistry can be useful to identify patients who may benefit from more aggressive therapies, but not as tools for case selection for FISH.
Collapse
Affiliation(s)
- Rui Almeida
- Department of Pathology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
| | - Carlos Abrantes
- Department of Anatomical Pathology, Hospital of the University of Coimbra (CHUC), Portugal
| | - Davide Gigliano
- Department of Pathology, Portuguese Oncology Institute of Porto, Porto, Portugal
| | - Rui Caetano Oliveira
- Department of Pathology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
| | - Paulo Teixeira
- Department of Pathology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
| | - Marta Viegas
- Molecular Pathology Laboratory, Instituto Português de Oncologia de Coimbra de Francisco Gentil, 3000-651 Coimbra, Portugal
| | - Ângelo Rodrigues
- Department of Pathology, Portuguese Oncology Institute of Porto, Porto, Portugal
| | - Maria José Julião
- Department of Pathology, Coimbra Hospital and University Centre, CHUC, EPE, 3000-075, Coimbra, Portugal
| |
Collapse
|
8
|
Pinto C, Cunha AL, Rodrigues Â, Dias R, Brandão C, Dinis-Ribeiro M. Diagnosis of MALT Lymphoma from Surveillance Endoscopy of a Patient with a CDH1 Gene Germline Mutation. GE Port J Gastroenterol 2022; 29:51-55. [PMID: 35111964 PMCID: PMC8787504 DOI: 10.1159/000514652] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/25/2020] [Accepted: 10/17/2020] [Indexed: 08/13/2023]
Abstract
Carriers of the mutated CDH1 gene have an increased risk of developing early-onset signet-ring cell (diffuse) gastric cancer. We present a case of a young patient with a confirmed mutation of the CDH1 gene, who was diagnosed with a gastric marginal zone B-cell lymphoma (MZL) of mucosa-associated lymphoid tissue (MALT lymphoma) from surveillance endoscopy. He underwent Helicobacter pylori eradication treatment and was subsequently submitted to a total prophylactic gastrectomy. The surgical specimen only revealed foci of signet-ring cell carcinoma (SRCC) in situ without lymphoma signs. We highlight here the occurrence of other pathology in high-risk patients as well as its possible influence on the decision to perform gastrectomy.
Collapse
Affiliation(s)
- Cláudia Pinto
- Gastroenterology Department, Portuguese Oncology Institute of Porto, Porto, Portugal
| | - Ana Luísa Cunha
- Pathology Department, Portuguese Oncology Institute of Porto, Porto, Portugal
| | - Ângelo Rodrigues
- Pathology Department, Portuguese Oncology Institute of Porto, Porto, Portugal
| | - Renata Dias
- Pathology Department, Portuguese Oncology Institute of Porto, Porto, Portugal
| | - Catarina Brandão
- Gastroenterology Department, Portuguese Oncology Institute of Porto, Porto, Portugal
| | - Mário Dinis-Ribeiro
- Gastroenterology Department, Portuguese Oncology Institute of Porto, Porto, Portugal
- Center for Research in Health Technologies and Information Systems (CINTESIS), Faculty of Medicine, Porto, Portugal
| |
Collapse
|
9
|
Guimarães N, Ribeiro T, Peyroteo M, Canotilho R, Correia AM, Petronilho S, Rodrigues Â, Pereira JC, Martins P, Videira JF, Jácome M, Abreu de Sousa J. Synchronous gastric adenocarcinoma and T-cell lymphoma – a unique case. Eur J Surg Oncol 2021. [DOI: 10.1016/j.ejso.2020.11.177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
10
|
Moreira I, Coelho S, Rodrigues Â, Patrão AS, Maurício MJ. Urachal carcinoma: A case of a rare neoplasm. Curr Probl Cancer 2021; 45:100711. [PMID: 33541722 DOI: 10.1016/j.currproblcancer.2021.100711] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2020] [Revised: 12/30/2020] [Accepted: 01/19/2021] [Indexed: 01/03/2023]
Abstract
INTRODUCTION Urachal carcinoma is a rare type of non-urothelial malignancy that arises from the urachal ligament, a remnant of fetal development. It frequently involves the dome of the bladder or its midline, with adenocarcinoma being the most common histological type. This malignancy is generally diagnosed in advanced stages and is associated with poor prognosis. CASE REPORT A 40-year-old woman was referred to hospital due to recurrent urinary tract infections. Imaging studies showed the presence of a 3.7 cm tumor in the bladder dome that extended to the posterior region of the umbilicus. A biopsy through cystoscopy confirmed the diagnosis of urachal carcinoma. Since there were no metastases, the patient underwent partial cystectomy and resection of the urachal ligament and the umbilicus. Surgical margins were negative and it was considered a complete resection. Nine months later, disease progression occurred, with peritoneal carcinomatosis, multiple adenopathies and a 4 cm mass in the pelvic cavity with invasion of the vagina, rectum, and sigmoid colon. She began palliative chemotherapy with cisplatine and 5-fluorouracil. After 7 cycles, progression was again observed, with an increase of the pelvic mass, vaginal and rectal hemorrhage, multiple intramuscular implants, bilateral axillary adenopathies, as well as lesion in the right breast, which was compatible with metastasis from urachal carcinoma. She underwent hemostatic radiotherapy to the pelvic mass and second line palliative chemotherapy with gemcitabine and paclitaxel. After 4 cycles, the patient clinically deteriorated and eventually died. CONCLUSION Urachal carcinoma is an aggressive malignancy. Although systemic treatment may be effective in disease control, a standard chemotherapy regimen is yet to be determined. Multicenter trials are needed to clarify the best treatment approach in these patients.
Collapse
Affiliation(s)
- Inês Moreira
- Oncology Department, Portuguese Institute of Oncology Francisco Gentil, Porto, Portugal.
| | - Sara Coelho
- Oncology Department, Portuguese Institute of Oncology Francisco Gentil, Porto, Portugal
| | - Ângelo Rodrigues
- Pathology Department, Portuguese Institute of Oncology Francisco Gentil, Porto, Portugal
| | - Ana Sofia Patrão
- Oncology Department, Portuguese Institute of Oncology Francisco Gentil, Porto, Portugal
| | | |
Collapse
|
11
|
Gigliano D, Lobo J, Lopes P, Julião I, Lobo F, Azevedo R, Henrique R, Rodrigues Â. Merkel cell carcinoma metastatic to the testis: report of a rare diagnosis and review of the literature. Autops Case Rep 2020; 11:e2020198. [PMID: 34277480 PMCID: PMC8101657 DOI: 10.4322/acr.2020.198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2020] [Accepted: 06/13/2020] [Indexed: 11/23/2022] Open
Abstract
Merkel cell carcinoma is an aggressive malignancy that frequently recurs/disseminates, but metastases to the genitourinary tract are rare. Only eight cases of Merkel cell carcinoma metastatic to the testis are reported. We describe the ninth case of this event and provide a review of the literature. A 58-year-old man diagnosed with Merkel cell carcinoma of the wrist, presented, 37 months later, a recurrence in the form of a testicular metastasis. The tumor consisted of a monotonous proliferation of small, blue, round cells, with immunoexpression of neuroendocrine markers and the typical dot-like paranuclear immunostaining for cytokeratin 20, in the absence of immunostaining for cytokeratin 7. The patient is alive with no evidence of disease. Clinicians should be aware of the possibility of metastatic dissemination to the testis since genital examination/imaging is not part of routine follow-up for these patients, but timely orchiectomy may be curative.
Collapse
Affiliation(s)
- Davide Gigliano
- Instituto Português de Oncologia do Porto, Serviço de Anatomia Patológica, Porto, Portugal.,Research Center of Portuguese Oncology Institute of Porto (GEBC CI-IPOP), Porto Comprehensive Cancer Center (P.CCC), Cancer Biology and Epigenetics Group, Porto, Portugal.,Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto (ICBAS-UP), Departamento de Patologia e Imunologia Molecular, Porto, Portugal
| | - João Lobo
- Instituto Português de Oncologia do Porto, Serviço de Anatomia Patológica, Porto, Portugal.,Research Center of Portuguese Oncology Institute of Porto (GEBC CI-IPOP), Porto Comprehensive Cancer Center (P.CCC), Cancer Biology and Epigenetics Group, Porto, Portugal.,Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto (ICBAS-UP), Departamento de Patologia e Imunologia Molecular, Porto, Portugal
| | - Paula Lopes
- Instituto Português de Oncologia do Porto, Serviço de Anatomia Patológica, Porto, Portugal.,Research Center of Portuguese Oncology Institute of Porto (GEBC CI-IPOP), Porto Comprehensive Cancer Center (P.CCC), Cancer Biology and Epigenetics Group, Porto, Portugal
| | - Ivo Julião
- Instituto Português de Oncologia do Porto, Serviço de Oncologia Médica, Porto, Portugal
| | - Francisco Lobo
- Instituto Português de Oncologia do Porto, Serviço de Urologia, Porto, Portugal
| | - Rosa Azevedo
- Instituto Português de Oncologia do Porto, Serviço de Anatomia Patológica, Porto, Portugal
| | - Rui Henrique
- Instituto Português de Oncologia do Porto, Serviço de Anatomia Patológica, Porto, Portugal.,Research Center of Portuguese Oncology Institute of Porto (GEBC CI-IPOP), Porto Comprehensive Cancer Center (P.CCC), Cancer Biology and Epigenetics Group, Porto, Portugal.,Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto (ICBAS-UP), Departamento de Patologia e Imunologia Molecular, Porto, Portugal
| | - Ângelo Rodrigues
- Instituto Português de Oncologia do Porto, Serviço de Anatomia Patológica, Porto, Portugal.,Research Center of Portuguese Oncology Institute of Porto (GEBC CI-IPOP), Porto Comprehensive Cancer Center (P.CCC), Cancer Biology and Epigenetics Group, Porto, Portugal.,Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto (ICBAS-UP), Departamento de Patologia e Imunologia Molecular, Porto, Portugal
| |
Collapse
|
12
|
Lobo J, Rodrigues Â, Guimarães R, Cantante M, Lopes P, Maurício J, Oliveira J, Jerónimo C, Henrique R. Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers. Cancers (Basel) 2019; 11:cancers11101535. [PMID: 31614500 PMCID: PMC6826711 DOI: 10.3390/cancers11101535] [Citation(s) in RCA: 41] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2019] [Revised: 09/28/2019] [Accepted: 10/08/2019] [Indexed: 01/08/2023] Open
Abstract
Background: The immune infiltrate plays an important part in testicular germ cell tumors, but it remains scarcely studied. We aimed at thoroughly characterizing the immune infiltrate and expression of immune checkpoints PD-L1/CTLA-4 and mismatch repair (MMR) proteins in these neoplasms, seeking for associations with patient outcome. Methods: A total of 162 consecutively diagnosed patients (2005–2018) were included. Immunostaining for PD-L1, CTLA-4 and MMR proteins was independently assessed both in immune cells (ICs) and tumor cells (TCs) of primary tumors and metastases, and characterization of IC populations was pursued. Results: PD-L1 and CTLA-4 positivity in ICs was frequent (85.5% and 96.3%). Patients with absent PD-L1 positive ICs exhibited significantly worse relapse-free survival (hazard ratio = 4.481, 95% CI 1.366–14.697, p = 0.013), both in univariable and multivariable analysis. Lower CD20 and CD3 IC infiltration in seminomas associated with higher disease stage (p = 0.0216, p = 0.0291). CTLA-4 TC intensity was significantly higher in yolk sac tumor, choriocarcinoma and teratoma, while PD-L1 TC positivity was significantly more frequent in choriocarcinoma. Both PD-L1 and CTLA-4 immunoexpression in ICs of metastatic samples was frequent (100% and 88.2%). MMR proteins were differentially expressed among the different tumor subtypes. Conclusions: Immune infiltrate/checkpoints associate with patients’ outcome, constituting novel (potentially targetable) disease biomarkers.
Collapse
Affiliation(s)
- João Lobo
- Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
- Cancer Biology and Epigenetics Group, Research Center of Portuguese Oncology Institute of Porto (GEBC CI-IPOP) and Porto Comprehensive Cancer Center (P.CCC), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
- Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal.
| | - Ângelo Rodrigues
- Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
- Cancer Biology and Epigenetics Group, Research Center of Portuguese Oncology Institute of Porto (GEBC CI-IPOP) and Porto Comprehensive Cancer Center (P.CCC), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
- Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal.
| | - Rita Guimarães
- Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
- Cancer Biology and Epigenetics Group, Research Center of Portuguese Oncology Institute of Porto (GEBC CI-IPOP) and Porto Comprehensive Cancer Center (P.CCC), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
| | - Mariana Cantante
- Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
- Cancer Biology and Epigenetics Group, Research Center of Portuguese Oncology Institute of Porto (GEBC CI-IPOP) and Porto Comprehensive Cancer Center (P.CCC), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
| | - Paula Lopes
- Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
- Cancer Biology and Epigenetics Group, Research Center of Portuguese Oncology Institute of Porto (GEBC CI-IPOP) and Porto Comprehensive Cancer Center (P.CCC), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
| | - Joaquina Maurício
- Department of Medical Oncology & Urology Clinic, Portuguese Oncology Institute of Porto (IPOP), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
| | - Jorge Oliveira
- Department of Urology & Urology Clinic, Portuguese Oncology Institute of Porto (IPOP), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
| | - Carmen Jerónimo
- Cancer Biology and Epigenetics Group, Research Center of Portuguese Oncology Institute of Porto (GEBC CI-IPOP) and Porto Comprehensive Cancer Center (P.CCC), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
- Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal.
| | - Rui Henrique
- Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
- Cancer Biology and Epigenetics Group, Research Center of Portuguese Oncology Institute of Porto (GEBC CI-IPOP) and Porto Comprehensive Cancer Center (P.CCC), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
- Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal.
| |
Collapse
|
13
|
Rodrigues Â, Castro M, Negrão L, Matias S, Águas F. International ovarian tumor analysis simple rules: The essential starting point for optimal management. Australas J Ultrasound Med 2019. [DOI: 10.1002/ajum.12153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Affiliation(s)
- Â. Rodrigues
- Gynecology Department Centro Hospitalar e Universitário Coimbra Portugal
| | - M.G. Castro
- Gynecology Department Centro Hospitalar e Universitário Coimbra Portugal
| | - L. Negrão
- Gynecology Department Centro Hospitalar e Universitário Coimbra Portugal
| | - S. Matias
- Gynecology Department Centro Hospitalar e Universitário Coimbra Portugal
| | - F. Águas
- Gynecology Department Centro Hospitalar e Universitário Coimbra Portugal
| |
Collapse
|
14
|
Rodrigues Â, Freitas R, Nogueira-Silva P, Jerónimo C, Henrique R. Biopsy sampling and histopathological markers for diagnosis of prostate cancer. Expert Rev Anticancer Ther 2014; 14:1323-36. [PMID: 25278357 DOI: 10.1586/14737140.2014.965688] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Prostate cancer is one of the most common malignant tumors and a leading cause of cancer-related morbidity and mortality. Irrespective of the method that allows for risk stratification of prostate cancer suspects, diagnosis relies on tissue sampling through prostate biopsy and subsequent histopathological evaluation. This provides critical information about disease aggressiveness, which is required for adequate patient management. Prostate biopsy methods have significantly evolved over the years, including the definition of indications, sampling schemes and use of imaging techniques (ultrasound and MRI) that allow for more accurate tissue sampling. In response to the challenges emerging from more precise collection of minute prostate tissue samples for analysis, histopathological assessment should include not only the observation of routinely stained sections, but also, and increasingly so, a series of ancillary techniques, especially immunohistochemistry, which increment the accuracy of prostate cancer diagnosis and may provide relevant information to guide patient management.
Collapse
Affiliation(s)
- Ângelo Rodrigues
- Department of Pathology, Portuguese Oncology Institute, Rua Dr. António Bernardino Almeida, 4200-072 - Porto, Portugal
| | | | | | | | | |
Collapse
|
15
|
Pinto J, Aguiar AT, Duarte H, Vilaverde F, Rodrigues Â, Krug JL. Simple and complex fibroadenomas: are there any distinguishing sonographic features? J Ultrasound Med 2014; 33:415-419. [PMID: 24567452 DOI: 10.7863/ultra.33.3.415] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
OBJECTIVES Complex fibroadenomas are fibroadenomas harboring 1 or more complex pathologic features: epithelial calcifications, apocrine metaplasia, sclerosing adenosis, and cysts larger than 3 mm. No sonographic features have been clearly defined for the distinction of simple fibroadenomas from complex ones, which are associated with an increased cancer risk. We aimed to evaluate the accuracy of sonographic features for the prediction of complexity in fibroadenomas. METHODS A total of 252 fibroadenomas were found at consecutive percutaneous needle or excisional surgical biopsy. Sixty-three were excluded because their respective imaging examinations were not recorded on digital support and consequently were not available. According to histologic diagnoses, fibroadenomas (n = 189) were classified into simple (n = 159) and complex (n = 30). The size, number, and sonographic features were assessed, and their respective accuracy rates for prediction of complexity were analyzed. RESULTS All patients were women. Complex fibroadenomas presented more frequently as solitary nodules (n = 21 [70%]) and were significantly larger than simple fibroadenomas (1.9 versus 1.3 cm; P = .009). Image predictors of complexity were an irregular shape (P< .001), noncircumscribed contours (indistinct, angular, microlobulated, or spiculated; P < .001), a complex echo structure (P < .001), the presence of microcalcifications (P = .002), and posterior acoustic enhancement (P < .001). By logistic multivariate regression, a complex echo structure (odds ratio [OR], 9.5; 95% confidence interval [CI], 2.8-32.3), noncircumscribed contours (OR, 3.7; 95% CI, 1.1-12.8), and posterior acoustic enhancement (OR, 4.0; 95% CI, 1.1-14.6) were independent predictors of complexity. Receiver operating characteristic curve analysis showed that a complex echo structure was the most accurate sonographic finding for identification of complex fibroadenomas (area under the curve, 0.74). CONCLUSIONS Certain sonographic features are associated with complex fibroadenomas and can help the radiologist decide which ones require biopsy.
Collapse
Affiliation(s)
- Joana Pinto
- Centro Hospitalar de Entre o Douro e Vouga, Rua Dr Cândido de Pinho, 4520-211 Santa Maria da Feira, Portugal.
| | | | | | | | | | | |
Collapse
|
16
|
Junqueira-Neto S, Vieira FQ, Montezuma D, Costa NR, Antunes L, Baptista T, Oliveira AI, Graça I, Rodrigues Â, Magalhães JS, Oliveira J, Henrique R, Jerónimo C. Phenotypic impact of deregulated expression of class I histone deacetylases in urothelial cell carcinoma of the bladder. Mol Carcinog 2013; 54:523-31. [DOI: 10.1002/mc.22117] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2013] [Revised: 11/05/2013] [Accepted: 11/07/2013] [Indexed: 11/09/2022]
Affiliation(s)
- Susana Junqueira-Neto
- Cancer Epigenetics Group; Research Center of the Portuguese Oncology Institute-Porto; Porto Portugal
| | - Filipa Q. Vieira
- Cancer Epigenetics Group; Research Center of the Portuguese Oncology Institute-Porto; Porto Portugal
- School of Allied Health Sciences ESTSP; Polytechnic of Porto; Porto Portugal
| | - Diana Montezuma
- Cancer Epigenetics Group; Research Center of the Portuguese Oncology Institute-Porto; Porto Portugal
- Department of Pathology; Portuguese Oncology Institute; Porto Portugal
| | - Natália R. Costa
- Cancer Epigenetics Group; Research Center of the Portuguese Oncology Institute-Porto; Porto Portugal
| | - Luís Antunes
- Department of Epidemiology; Portuguese Oncology Institute; Porto Portugal
| | - Tiago Baptista
- Cancer Epigenetics Group; Research Center of the Portuguese Oncology Institute-Porto; Porto Portugal
| | - Ana Isabel Oliveira
- Cancer Epigenetics Group; Research Center of the Portuguese Oncology Institute-Porto; Porto Portugal
| | - Inês Graça
- Cancer Epigenetics Group; Research Center of the Portuguese Oncology Institute-Porto; Porto Portugal
- School of Allied Health Sciences ESTSP; Polytechnic of Porto; Porto Portugal
| | - Ângelo Rodrigues
- Department of Pathology; Portuguese Oncology Institute; Porto Portugal
| | - José S. Magalhães
- Department of Urology; Portuguese Oncology Institute; Porto Portugal
| | - Jorge Oliveira
- Department of Urology; Portuguese Oncology Institute; Porto Portugal
| | - Rui Henrique
- Cancer Epigenetics Group; Research Center of the Portuguese Oncology Institute-Porto; Porto Portugal
- Department of Pathology; Portuguese Oncology Institute; Porto Portugal
- Department of Pathology and Molecular Immunology; Institute of Biomedical Sciences Abel Salazar, University of Porto; Porto Portugal
| | - Carmen Jerónimo
- Cancer Epigenetics Group; Research Center of the Portuguese Oncology Institute-Porto; Porto Portugal
- Department of Pathology and Molecular Immunology; Institute of Biomedical Sciences Abel Salazar, University of Porto; Porto Portugal
| |
Collapse
|
17
|
Estevinho F, Sousa N, Rodrigues Â, Carneiro E, Souto J, Begonha R, Maurício J. [Spinal cord compression by testicular germ cell tumor: case report]. ACTA MEDICA PORT 2012; 25:461-465. [PMID: 23534600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2012] [Accepted: 10/19/2012] [Indexed: 06/02/2023]
Abstract
Malignant spinal cord compression occurs in 2.5% - 5% cancer patients. Early diagnosis and therapeutic intervention are critical for pain control and improvement of any neurological deficit. Treatment should be directed to the underlying disease together with appropriate symptom management. The case of a man with tetraparesis of 24 hours duration is presented. He had surgery five days earlier because of a testicular tumor and spinal magnetic resonance imaging (MRI) showed spinal cord compression by a soft tissue mass between C7 and D2. After confirming the diagnosis of mixed germ cell tumor, stage IIIC, the patient began chemotherapy with progressive neurological improvement. Two years after diagnosis the patient presents a slight reduction of strength in the right hand and remains without any evidence of disease. This case illustrates the importance of early diagnosis of spinal cord compression and one of the main indications for the use of chemotherapy as the treatment for an oncologic emergency.
Collapse
Affiliation(s)
- Fernanda Estevinho
- Serviço de Oncologia Médica, Instituto Português de Oncologia, Porto, Portugal
| | | | | | | | | | | | | |
Collapse
|
18
|
Barros-Silva JD, Ribeiro FR, Rodrigues Â, Cruz R, Martins AT, Jerónimo C, Henrique R, Teixeira MR. Relative 8q gain predicts disease-specific survival irrespective of the TMPRSS2-ERG fusion status in diagnostic biopsies of prostate cancer. Genes Chromosomes Cancer 2011; 50:662-671. [DOI: 10.1002/gcc.20888] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
|